A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation.
BACKGROUND
Warfarin therapy has proved safe and effective in a number of randomized controlled trials of stroke prophylaxis in patients with nonvalvular atrial fibrillation (NVAF), reducing the risk of stroke in these patients by two thirds. However, participants in the clinical trials were carefully selected and younger than patients in actual clinical practice.


OBJECTIVE
This analysis sought to determine whether the results of clinical trials in patients with NV can be extrapolated to the general population seen in clinical practice.


METHODS
A MEDLINE search from 1966 to the present was used to identify observational trials of anticoagulation in patients with NVAF that addressed warfarin use, anticoagulation control, efficacy, and complications. The search terms used were atrial fibrillation and anticoagulation.


RESULTS
Although warfarin prophylaxis against stroke in patients with NVAF appeared to be as well tolerated and effective in clinical practice as in clinical trials, it was generally underused, particularly in the elderly. Anticoagulation control was not as good in clinical practice as in clinical trials, although the rates of stroke and major bleeding were comparable.


CONCLUSIONS
Judicious use of warfarin, tailored to individual stroke risk, seems to be a reasonable policy. Warfarin therapy increases quality-adjusted survival in patients at high risk for stroke, and it is recommended for medium-risk patients unless their risk of bleeding is high or their quality of life while taking warfarin would be poor. Patients at a low risk for stroke will have equivalent health outcomes and incur lower costs if treated with aspirin. Despite the increased risk of hemorrhage in elderly patients, the net benefit of warfarin therapy is greater in this age group because of the higher risk of stroke. Active involvement of patients and their caregivers in an anticoagulation service setting may improve outcomes of anticoagulation therapy.
Abdelhafiz
A H
AH
Acute and Elderly Medicine, Northern General Hospital, Sheffield, South Yorkshire, England.
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000639:trends; D003362:Cost-Benefit Analysis; D006801:Humans; D016239:MEDLINE; D020521:Stroke / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin